$SKIN
Beauty Health Co Stock $skin

$skin Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024010638 Filed on March 12, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$81.40M	$96.82M	$398.0M
YoY Change	-5.65%	-1.34%	8.78%
Cost Of Revenue	$33.04M	$13.24M	$242.9M
YoY Change	2.7%	-59.84%	110.22%
Gross Profit	$48.36M	$83.59M	$155.1M
YoY Change	-10.61%	28.25%	-38.04%
Gross Profit Margin	59.41%	86.33%	38.97%
Selling, General & Admin	$62.55M	$61.00M	$275.9M
YoY Change	-9.46%	-6.05%	3.66%
% of Gross Profit	129.33%	72.98%	177.89%
Research & Development	$2.807M	$3.046M	$10.10M
YoY Change	20.16%	110.65%	19.64%
% of Gross Profit	5.8%	3.64%	6.51%
Depreciation & Amortization	$2.773M	$9.288M	$11.33M
YoY Change	51.2%	-9.34%	58.18%
% of Gross Profit	5.73%	11.11%	7.31%
Operating Expenses	$65.35M	$64.05M	$286.0M
YoY Change	-8.49%	-7.1%	4.15%
Operating Profit	-$16.99M	$19.54M	-$130.9M
YoY Change	-1.84%	-618.99%	439.2%
Interest Expense	$3.029M	$6.142M	$13.65M
YoY Change	-11.35%	39.09%	-201.92%
% of Operating Profit		31.43%
Other Income/Expense, Net	$16.09M	$3.418M	$5.200M
YoY Change	3748.56%	76.0%	-415.15%
Pretax Income	-$1.338M	-$8.800M	-$101.9M
YoY Change	-94.84%	-439.38%	-326.26%
Income Tax	-$700.0K	$603.0K	-$1.773M
% Of Pretax Income
Net Earnings	-$679.0K	-$9.403M	-$100.1M
YoY Change	-96.95%	-346.47%	-325.57%
Net Earnings / Revenue	-0.83%	-9.71%	-25.16%
Basic Earnings Per Share	-$0.01		-$0.76
Diluted Earnings Per Share	-$0.10	-$0.07	-$0.76
COMMON SHARES
Basic Shares Outstanding	123.4M shares	131.3M shares	131.7M shares
Diluted Shares Outstanding	144.5M shares		131.7M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$444.6M	$523.0M	$523.0M
YoY Change	-16.47%	-7.95%	-7.95%
Cash & Equivalents	$444.6M	$523.0M	$523.0M
Short-Term Investments
Other Short-Term Assets	$25.60M	$28.88M	$28.88M
YoY Change	17.97%	8.16%	8.16%
Inventory	$95.72M	$91.32M	$91.32M
Prepaid Expenses
Receivables	$47.67M	$54.70M	$54.70M
Other Receivables	$1.204M	$332.0K	$332.0K
Total Short-Term Assets	$614.8M	$698.3M	$698.3M
YoY Change	-17.86%	-11.51%	-11.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$28.43M	$26.35M	$26.35M
YoY Change	-16.38%	-22.1%	-22.1%
Goodwill	$125.4M	$125.8M
YoY Change	0.15%	0.98%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$15.78M	$16.04M	$16.57M
YoY Change	0.99%	13.03%	10.43%
Total Long-Term Assets	$229.9M	$230.9M	$230.9M
YoY Change	-6.7%	5.03%	5.03%
TOTAL ASSETS
Total Short-Term Assets	$614.8M	$698.3M	$698.3M
Total Long-Term Assets	$229.9M	$230.9M	$230.9M
Total Assets	$844.7M	$929.1M	$929.1M
YoY Change	-15.1%	-7.91%	-7.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$37.31M	$44.77M	$44.77M
YoY Change	8.69%	47.58%	47.58%
Accrued Expenses	$24.40M	$19.85M	$41.50M
YoY Change	85.53%	30.71%	-0.76%
Deferred Revenue		$450.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$93.57M	$115.0M	$115.0M
YoY Change	29.36%	57.3%	57.3%
LONG-TERM LIABILITIES
Long-Term Debt	$665.5M	$738.4M	$738.4M
YoY Change	-9.48%	0.58%	0.58%
Other Long-Term Liabilities	$2.617M	$2.767M	$15.64M
YoY Change	-92.91%	-90.17%	-44.46%
Total Long-Term Liabilities	$2.617M	$2.767M	$754.0M
YoY Change	-99.66%	-99.64%	-1.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$93.57M	$115.0M	$115.0M
Total Long-Term Liabilities	$2.617M	$2.767M	$754.0M
Total Liabilities	$781.4M	$869.7M	$869.7M
YoY Change	-7.77%	3.86%	3.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$479.5M	-$478.9M
YoY Change	18.77%	27.93%
Common Stock	$12.00K	$12.00K
YoY Change	-14.29%	-14.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$63.30M	$59.39M	$59.39M
YoY Change
Total Liabilities & Shareholders Equity	$844.7M	$929.1M	$929.1M
YoY Change	-15.1%	-7.91%	-7.91%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$679.0K	-$9.403M	-$100.1M
YoY Change	-96.95%	-346.47%	-325.57%
Depreciation, Depletion And Amortization	$2.773M	$9.288M	$11.33M
YoY Change	51.2%	-9.34%	58.18%
Cash From Operating Activities	-$16.85M	-$5.170M	$21.75M
YoY Change	29.55%	-4.13%	-120.4%
INVESTING ACTIVITIES
Capital Expenditures	$344.0K	$2.168M	$3.825M
YoY Change	-85.17%	-23.23%	-64.74%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$2.000K	$0.00
YoY Change	-100.0%		-100.0%
Cash From Investing Activities	-$1.802M	-$2.168M	-$31.51M
YoY Change	-91.69%	-23.23%	66.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$30.16M
YoY Change			-81.15%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$58.62M	-31.36M	-$37.45M
YoY Change	2570.52%	-69.4%	-81.75%
NET CHANGE
Cash From Operating Activities	-$16.85M	-5.170M	$21.75M
Cash From Investing Activities	-$1.802M	-2.168M	-$31.51M
Cash From Financing Activities	-$58.62M	-31.36M	-$37.45M
Net Change In Cash	-$77.27M	-38.70M	-$47.21M
YoY Change	109.48%	-65.04%	-85.73%
FREE CASH FLOW
Cash From Operating Activities	-$16.85M	-$5.170M	$21.75M
Capital Expenditures	$344.0K	$2.168M	$3.825M
Free Cash Flow	-$17.20M	-$7.338M	$17.93M
YoY Change	12.19%	-10.7%	-115.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-11919000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-100116000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-380263000	usd
CY2023	us-gaap	Interest Expense InterestExpense	13649000	usd
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001818093
CY2023	us-gaap	Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#CostOfRevenue
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39565
CY2023	dei	Entity Registrant Name EntityRegistrantName	The Beauty Health Company
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1908962
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2165 Spring Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Long Beach
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90806
CY2023	dei	City Area Code CityAreaCode	800
CY2023	dei	Local Phone Number LocalPhoneNumber	603-4996
CY2023	dei	Security12b Title Security12bTitle	Class A Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	SKIN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	728800000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	123427416	shares
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	523025000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	568197000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6604000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2929000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	54697000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	76494000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	91321000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	109656000	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	332000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	1280000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	28877000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	27648000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	698252000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	783275000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	14226000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	18184000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12120000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15637000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	62123000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	46386000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	125818000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	124593000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	531000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	815000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16043000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14193000	usd
CY2023Q4	us-gaap	Assets Assets	929113000	usd
CY2022Q4	us-gaap	Assets Assets	1003083000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	44768000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	28467000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22028000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	21677000	usd
CY2023Q4	skin	Syndeo Program Reserves SyndeoProgramReserves	21009000	usd
CY2022Q4	skin	Syndeo Program Reserves SyndeoProgramReserves	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4598000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4958000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2759000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1429000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19846000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15183000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	115008000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	71714000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9319000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12689000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	702000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2011000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	3555000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	15473000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	738372000	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	734143000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2767000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	869723000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	836030000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	320000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	320000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	122899002	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	122899002	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	132214695	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	132214695	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	12000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	14000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	541281000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	550320000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3036000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4530000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-478867000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-378751000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	59390000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	167053000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	929113000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1003083000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	397991000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	365876000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	260086000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	242878000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	117097000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	81548000	usd
CY2023	us-gaap	Gross Profit GrossProfit	155113000	usd
CY2022	us-gaap	Gross Profit GrossProfit	248779000	usd
CY2021	us-gaap	Gross Profit GrossProfit	178538000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	144496000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	160076000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	111583000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10102000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8444000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8195000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	131432000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	106100000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	98688000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	286030000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	274620000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	218466000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-25841000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-39928000	usd
CY2022	us-gaap	Interest Expense InterestExpense	13392000	usd
CY2021	us-gaap	Interest Expense InterestExpense	11777000	usd
CY2023	skin	Reverse Recapitalization Contingent Consideration Change In Amount Of Contingent Consideration Liability ReverseRecapitalizationContingentConsiderationChangeInAmountOfContingentConsiderationLiability	0	usd
CY2022	skin	Reverse Recapitalization Contingent Consideration Change In Amount Of Contingent Consideration Liability ReverseRecapitalizationContingentConsiderationChangeInAmountOfContingentConsiderationLiability	0	usd
CY2021	skin	Reverse Recapitalization Contingent Consideration Change In Amount Of Contingent Consideration Liability ReverseRecapitalizationContingentConsiderationChangeInAmountOfContingentConsiderationLiability	47100000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1773000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	44224000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1494000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3273000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1499000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-98622000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	40951000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.71
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.71
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	131680605	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	147554090	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102114949	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	131680605	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	148506312	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102114949	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-30567000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-378764000	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	9341000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	136575000	usd
CY2021	skin	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	182960000	usd
CY2021	skin	Adjustments To Additional Paid In Capital Option Indexed To Issuers Equity AdjustmentsToAdditionalPaidInCapitalOptionIndexedToIssuersEquity	90150000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	457720000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12418000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1499000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	298034000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	44224000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	500000	usd
CY2022	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	160000000	usd
CY2022	skin	Purchase Of Equity Forward Contract In Connection With Accelerated Share Repurchase PurchaseOfEquityForwardContractInConnectionWithAcceleratedShareRepurchase	40000000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	927000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28495000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3273000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	167053000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	167053000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-100116000	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1310000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3036000	usd
CY2023	us-gaap	Accelerated Share Repurchase Program Adjustment AcceleratedShareRepurchaseProgramAdjustment	-2240000	usd
CY2023	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	30457000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	22544000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1494000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	59390000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-100116000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	44224000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-378764000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	22544000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	28495000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	12418000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	20907000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14852000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13297000	usd
CY2023	us-gaap	Depreciation Depreciation	11332000	usd
CY2022	us-gaap	Depreciation Depreciation	7164000	usd
CY2021	us-gaap	Depreciation Depreciation	4486000	usd
CY2023	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	2436000	usd
CY2022	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	857000	usd
CY2021	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	147000	usd
CY2023	skin	Write Off And Amortization Of Deferred Debt Issuance Costs WriteOffAndAmortizationOfDeferredDebtIssuanceCosts	4229000	usd
CY2022	skin	Write Off And Amortization Of Deferred Debt Issuance Costs WriteOffAndAmortizationOfDeferredDebtIssuanceCosts	4229000	usd
CY2021	skin	Write Off And Amortization Of Deferred Debt Issuance Costs WriteOffAndAmortizationOfDeferredDebtIssuanceCosts	4061000	usd
CY2023	skin	Inventory Obsolescence InventoryObsolescence	19568000	usd
CY2022	skin	Inventory Obsolescence InventoryObsolescence	0	usd
CY2021	skin	Inventory Obsolescence InventoryObsolescence	0	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	18272000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	5144000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	1134000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5153000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1622000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	854000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-11919000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-78343000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	277315000	usd
CY2023	skin	Reverse Recapitalization Contingent Consideration Change In Amount Of Contingent Consideration Liability ReverseRecapitalizationContingentConsiderationChangeInAmountOfContingentConsiderationLiability	0	usd
CY2022	skin	Reverse Recapitalization Contingent Consideration Change In Amount Of Contingent Consideration Liability ReverseRecapitalizationContingentConsiderationChangeInAmountOfContingentConsiderationLiability	0	usd
CY2021	skin	Reverse Recapitalization Contingent Consideration Change In Amount Of Contingent Consideration Liability ReverseRecapitalizationContingentConsiderationChangeInAmountOfContingentConsiderationLiability	47100000	usd
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	5988000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	10423000	usd
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	5733000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-16520000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	32025000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	31013000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	22617000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	84363000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7288000	usd
CY2023	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	3666000	usd
CY2022	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-3871000	usd
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-35000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3285000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	17718000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5067000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	15783000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-262000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10523000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	26936000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3357000	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	24784000	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1282000	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	665000	usd
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-594000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	7597000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	12078000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	7522000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	21750000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-106600000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28361000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	9224000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6547000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4415000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3825000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10847000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11201000	usd
CY2023	skin	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	18458000	usd
CY2022	skin	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	1475000	usd
CY2021	skin	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	0	usd
CY2023	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	usd
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	usd
CY2021	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	22896000	usd
CY2023	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	usd
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	usd
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-781000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31507000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18869000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37731000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	30155000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	160000000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023	skin	Payment Of Accelerated Share Repurchases PaymentOfAcceleratedShareRepurchases	2240000	usd
CY2022	skin	Payment Of Accelerated Share Repurchases PaymentOfAcceleratedShareRepurchases	0	usd
CY2021	skin	Payment Of Accelerated Share Repurchases PaymentOfAcceleratedShareRepurchases	0	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3234000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	927000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1819000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	750000000	usd
CY2023	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	0	usd
CY2022	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	0	usd
CY2021	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	90150000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	188378000	usd
CY2023	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	usd
CY2022	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	usd
CY2021	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	5000000	usd
CY2023	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	usd
CY2022	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	usd
CY2021	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	5000000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	21341000	usd
CY2023	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	usd
CY2022	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	usd
CY2021	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	225486000	usd
CY2023	skin	Proceed From Business Combination ProceedFromBusinessCombination	0	usd
CY2022	skin	Proceed From Business Combination ProceedFromBusinessCombination	0	usd
CY2021	skin	Proceed From Business Combination ProceedFromBusinessCombination	357634000	usd
CY2023	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	0	usd
CY2022	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	40000000	usd
CY2021	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	0	usd
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	usd
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-4315000	usd
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-37448000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-205242000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	959035000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-47205000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-330711000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	892943000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2033000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2978000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-543000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	568197000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	901886000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9486000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	523025000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	568197000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	901886000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	9375000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	9818000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	10249000	usd
CY2023	skin	Stock Issued Asset Acquisition StockIssuedAssetAcquisition	1310000	usd
CY2022	skin	Stock Issued Asset Acquisition StockIssuedAssetAcquisition	500000	usd
CY2021	skin	Stock Issued Asset Acquisition StockIssuedAssetAcquisition	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2269000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-1339000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1700000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	136575000	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1 NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1	0	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1 NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1	0	usd
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1 NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1	6623000	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	0	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	0	usd
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	2153000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	783000	usd
CY2023	skin	Stock Issued Business Acquisition StockIssuedBusinessAcquisition	0	usd
CY2022	skin	Stock Issued Business Acquisition StockIssuedBusinessAcquisition	0	usd
CY2021	skin	Stock Issued Business Acquisition StockIssuedBusinessAcquisition	9341000	usd
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	5100000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	1100000	usd
CY2021Q2	skin	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	653.109
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates and assumptions in preparing consolidated financial statements</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing its consolidated financial statements in conformity with GAAP, the Company makes assumptions, estimates, and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of net sales and expenses during the reported periods. On an ongoing basis, the Company evaluates its estimates, including, among others, those related to revenue related reserves, allowance for estimated credit losses, the realizability of inventory, fair value measurements including </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock, warrant liabilities and earn-out shares liability </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuations, useful lives of property and equipment, goodwill and finite-lived intangible assets, accounting for income taxes, stock-based compensation expense and commitments and contingencies. The Company’s estimates are based on historical experience and on its future expectations that are believed to be reasonable. The combination of these factors forms the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from current estimates and those differences may be material.</span></div>
CY2023	skin	Inventory Obsolescence InventoryObsolescence	19600000	usd
CY2021Q2	skin	Reverse Recapitalization Equity Interest Issued Or Issuable Number Of Shares ReverseRecapitalizationEquityInterestIssuedOrIssuableNumberOfShares	7500000	shares
CY2021Q3	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	4	business
CY2021Q3	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	4	business
CY2021Q3	skin	Stock Issued During Period Shares Reverse Recapitalization StockIssuedDuringPeriodSharesReverseRecapitalization	7500000	shares
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	6000000	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2000000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	4000000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	2000000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	2000000	usd
CY2023	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	Payment terms vary by customer but typically provide for the customer to pay within less than a year; however, the Company provides options for qualified customers through third party financing companies, generally without recourse to the Company, or through internal financing to pay for Delivery Systems over 12 monthly installments or less. Under certain limited arrangements, which are not material, the customer’s receivable balance is with recourse whereby we are responsible for repaying the financing company should the customer default.
CY2023	us-gaap	Advertising Expense AdvertisingExpense	2300000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	3800000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	3200000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company primarily maintains its operating cash balance with a major financial institution. At times, cash balances may be in excess of Federal Deposit Insurance Corporation insurance limits. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk in this area. Accounts receivable are unsecured and the Company is at risk to the extent such amounts become uncollectible. Concentration of credit risk with respect to accounts receivable is generally mitigated by the Company performing ongoing credit evaluations of its customers.</span></div>
CY2021Q2	skin	Common Stock Convertible Conversion Ratio CommonStockConvertibleConversionRatio	1
CY2021Q2	skin	Reverse Recapitalization Consideration Received ReverseRecapitalizationConsiderationReceived	783000000	usd
CY2021Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	350000000	usd
CY2021Q2	skin	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	433000000	usd
CY2021Q2	skin	Reverse Recapitalization Cash Paid To Shareholders ReverseRecapitalizationCashPaidToShareholders	368000000	usd
CY2021Q2	skin	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	57000000	usd
CY2021Q2	skin	Stock Converted Reverse Recapitalization StockConvertedReverseRecapitalization	35501743	shares
CY2021Q2	skin	Reverse Recapitalization Cash Paid For Working Capital Adjustments ReverseRecapitalizationCashPaidForWorkingCapitalAdjustments	900000	usd
CY2021Q2	skin	Stock Issued During Period Shares Reverse Recapitalization Working Capital Adjustment StockIssuedDuringPeriodSharesReverseRecapitalizationWorkingCapitalAdjustment	70860	shares
CY2021	skin	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	433382000	usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	350000000	usd
CY2021	skin	Reverse Recapitalization Cash Paid To Shareholders ReverseRecapitalizationCashPaidToShareholders	367870000	usd
CY2021	skin	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	56976000	usd
CY2021	skin	Reverse Recapitalization Cash Paid For Working Capital Adjustments ReverseRecapitalizationCashPaidForWorkingCapitalAdjustments	902000	usd
CY2021	skin	Proceeds From Reverse Recapitalization Transaction ProceedsFromReverseRecapitalizationTransaction	357634000	usd
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	35000000	shares
CY2021Q2	skin	Stock Issued During Period Shares Reverse Recapitalization StockIssuedDuringPeriodSharesReverseRecapitalization	89827310	shares
CY2021Q2	skin	Stock Converted Reverse Recapitalization StockConvertedReverseRecapitalization	35501743	shares
CY2021Q2	skin	Stock Issued During Period Shares Reverse Recapitalization Working Capital Adjustment StockIssuedDuringPeriodSharesReverseRecapitalizationWorkingCapitalAdjustment	70860	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	125399913	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54358	shares
CY2021Q2	skin	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	653.109
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	397991000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	365876000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	260086000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	397991000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	365876000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	260086000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2929000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5153000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	1478000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6604000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	24406000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	38373000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	66915000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	71283000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	91321000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	109656000	usd
CY2023	skin	Inventory Obsolescence InventoryObsolescence	19600000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	18300000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	10458000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5511000	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	7565000	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	10523000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	4005000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5643000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22028000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	21677000	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	4971000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	4904000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3914000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2348000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2344000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2344000	usd
CY2023Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	0	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1819000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8617000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3768000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19846000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15183000	usd
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	26346000	usd
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	33821000	usd
CY2023Q4	us-gaap	Nontrade Receivables NontradeReceivables	15000000	usd
CY2022Q4	us-gaap	Nontrade Receivables NontradeReceivables	6000000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12120000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15637000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4598000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4958000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9319000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12689000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	13917000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	17647000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	5200000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	5000000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	3300000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4816000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2110000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1744000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1228000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1056000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4162000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15116000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1199000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	13917000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	5419000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2981000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	3041000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1181000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4476000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5707000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0318
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0298
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0275
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	19953000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	12494000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	14226000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	18184000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	124593000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	123694000	usd
CY2020Q4	us-gaap	Goodwill Goodwill	98531000	usd
CY2023	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	0	usd
CY2022	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	2154000	usd
CY2021	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	26600000	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	1225000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-1255000	usd
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-1437000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	125818000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	124593000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	123694000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	149392000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	87269000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	62123000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	114806000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	68420000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	46386000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	19698000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	10356000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	9029000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2189000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1735000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	6703000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4526000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	11811000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	62123000	usd
CY2021Q3	skin	Debt Instrument Debt Default Default Interest Rate Maximum DebtInstrumentDebtDefaultDefaultInterestRateMaximum	0.0100
CY2021	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	2300000	usd
CY2021	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	2000000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-104161000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	42080000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-378831000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	2272000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	3259000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1808000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-101889000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	45339000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-380639000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	34000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	407000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-727000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	216000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	306000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	513000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3793000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4043000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2902000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1521000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-4137000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-257000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2952000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-633000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-166000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-80000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1046000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1364000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-364000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5816000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1787000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3396000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1773000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1115000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1875000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-21398000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	9521000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-79935000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3083000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.030
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1041000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.023
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1041000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.003
CY2023	skin	Effective Income Tax Rate Reconciliation Officer Compensation Amount EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount	844000	usd
CY2023	skin	Effective Income Tax Rate Reconciliation Officer Compensation Percent EffectiveIncomeTaxRateReconciliationOfficerCompensationPercent	-0.008
CY2022	skin	Effective Income Tax Rate Reconciliation Officer Compensation Amount EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount	2323000	usd
CY2022	skin	Effective Income Tax Rate Reconciliation Officer Compensation Percent EffectiveIncomeTaxRateReconciliationOfficerCompensationPercent	0.051
CY2021	skin	Effective Income Tax Rate Reconciliation Officer Compensation Amount EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount	486000	usd
CY2021	skin	Effective Income Tax Rate Reconciliation Officer Compensation Percent EffectiveIncomeTaxRateReconciliationOfficerCompensationPercent	-0.001
CY2023	skin	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Amount EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsAmount	-2503000	usd
CY2023	skin	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	0.025
CY2022	skin	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Amount EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsAmount	-16452000	usd
CY2022	skin	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	-0.363
CY2021	skin	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Amount EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsAmount	58236000	usd
CY2021	skin	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	-0.153
CY2023	skin	Effective Income Tax Rate Reconciliation Contingent Consideration Amount EffectiveIncomeTaxRateReconciliationContingentConsiderationAmount	0	usd
CY2023	skin	Effective Income Tax Rate Reconciliation Contingent Consideration Percent EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent	0
CY2022	skin	Effective Income Tax Rate Reconciliation Contingent Consideration Amount EffectiveIncomeTaxRateReconciliationContingentConsiderationAmount	0	usd
CY2022	skin	Effective Income Tax Rate Reconciliation Contingent Consideration Percent EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent	0
CY2021	skin	Effective Income Tax Rate Reconciliation Contingent Consideration Amount EffectiveIncomeTaxRateReconciliationContingentConsiderationAmount	9891000	usd
CY2021	skin	Effective Income Tax Rate Reconciliation Contingent Consideration Percent EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent	-0.026
CY2023	skin	Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Costs Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsAmount	0	usd
CY2023	skin	Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Costs Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsPercent	0
CY2022	skin	Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Costs Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsAmount	-32000	usd
CY2022	skin	Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Costs Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsPercent	-0.001
CY2021	skin	Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Costs Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsAmount	3312000	usd
CY2021	skin	Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Costs Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsPercent	-0.009
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5072000	usd
CY2023Q4	skin	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	3191000	usd
CY2022Q4	skin	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	4469000	usd
CY2023Q4	skin	Deferred Tax Assets Capitalized Research DeferredTaxAssetsCapitalizedResearch	5305000	usd
CY2022Q4	skin	Deferred Tax Assets Capitalized Research DeferredTaxAssetsCapitalizedResearch	1730000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1611000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	685000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2922000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.029
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	338000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.003
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-10000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	475000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	824000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.008
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	900000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.020
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	152000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	2183000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.021
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	18400000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.181
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6242000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.138
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4755000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.012
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1348000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.013
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1464000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.032
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2098000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1773000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.017
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1115000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.024
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1875000	usd
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.005
CY2023Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	23000	usd
CY2022Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	55000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	5807000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1608000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	4944000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	4772000	usd
CY2023Q4	skin	Deferred Tax Assets Accounts Receivable DeferredTaxAssetsAccountsReceivable	1563000	usd
CY2022Q4	skin	Deferred Tax Assets Accounts Receivable DeferredTaxAssetsAccountsReceivable	625000	usd
CY2023Q4	skin	Deferred Tax Assets Section163j Limitation DeferredTaxAssetsSection163jLimitation	6031000	usd
CY2022Q4	skin	Deferred Tax Assets Section163j Limitation DeferredTaxAssetsSection163jLimitation	4782000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12379000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3680000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4032000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	5582000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	434000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	435000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2506000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	3966000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	44886000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	27478000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	6713000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2165000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3852000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11818000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	13835000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	33239000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14839000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	171000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1196000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	531000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	815000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	702000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2011000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	171000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1196000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	18400000	usd
CY2023Q4	skin	Valuation Allowance Deferred Tax Asset If Released Tax Benefit In Continuing Operations ValuationAllowanceDeferredTaxAssetIfReleasedTaxBenefitInContinuingOperations	33200000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1100000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	700000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	674000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	210000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	230000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	260000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	112000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	36000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	312000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	240000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1104000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	674000	usd
CY2023	skin	Proceeds From Employee Retention Credit ProceedsFromEmployeeRetentionCredit	5400000	usd
CY2023	skin	Defined Contribution Plan Eligible To Participate Service Period DefinedContributionPlanEligibleToParticipateServicePeriod	P1M
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3000000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2200000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1400000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5601770	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.21
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M2D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	31000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	12.85
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1431038	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	17.34
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	407312	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	18.97
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3732420	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.00
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M23D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2071735	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	13.94
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y2M12D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3732420	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	14.00
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M23D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8600000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	9700000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	2700000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	700000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22544000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28495000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12418000	usd
CY2023Q3	skin	Litigation Settlement Amount Awarded From Other Party Quarterly Payment Amount LitigationSettlementAmountAwardedFromOtherPartyQuarterlyPaymentAmount	100000	usd
CY2023Q3	skin	Number Of Quarterly Payments NumberOfQuarterlyPayments	13	payment
CY2023Q3	skin	Litigation Settlement Amount Awarded From Other Party Quarterly Payment Amount LitigationSettlementAmountAwardedFromOtherPartyQuarterlyPaymentAmount	100000	usd
CY2023Q3	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	1400000	usd
CY2023Q4	us-gaap	Proceeds From Legal Settlements ProceedsFromLegalSettlements	100000	usd
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	73700000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	320000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	skin	Common Stock Voting Rights Votes CommonStockVotingRightsVotes	1	vote
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	122899002	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	122899002	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	132214695	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	132214695	shares
CY2022Q4	skin	Number Of Stock Repurchase Programs NumberOfStockRepurchasePrograms	2	program
CY2022Q3	skin	Number Of Stock Repurchase Programs NumberOfStockRepurchasePrograms	2	program
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-100116000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	44224000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-378764000	usd
CY2023	skin	Warrant Down Round Feature Decrease In Net Income To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeToCommonShareholderAmount	0	usd
CY2022	skin	Warrant Down Round Feature Decrease In Net Income To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeToCommonShareholderAmount	78343000	usd
CY2021	skin	Warrant Down Round Feature Decrease In Net Income To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeToCommonShareholderAmount	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-100116000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-34119000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-378764000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	131680605	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	147554090	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102114949	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	952222	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	131680605	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	148506312	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102114949	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.71
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.71
CY2023	us-gaap	Restructuring Charges RestructuringCharges	7200000	usd
CY2023	skin	Outstanding Liabilities For Consulting Expenses OutstandingLiabilitiesForConsultingExpenses	2400000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	298000000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	81548000	usd
CY2021	us-gaap	Gross Profit GrossProfit	178538000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-39928000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-380639000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1875000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-378764000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-380263000	usd
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.71
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.71
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-378764000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7288000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5067000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	109656000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	27648000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	783275000	usd
CY2022Q4	us-gaap	Assets Assets	1003083000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	28467000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1429000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	71714000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	836030000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-378751000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	167053000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1003083000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	117097000	usd
CY2022	us-gaap	Gross Profit GrossProfit	248779000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-25841000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1296000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	45339000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1115000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	44224000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	40951000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	44224000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	84363000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	17718000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-262000	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	665000	usd

Files In Submission

Name	View Source	Status
0001628280-24-010638-index-headers.html	Edgar Link	pending
0001628280-24-010638-index.html	Edgar Link	pending
0001628280-24-010638.txt	Edgar Link	pending
0001628280-24-010638-xbrl.zip	Edgar Link	pending
ex211-subsidiariesofthereg.htm	Edgar Link	pending
ex231-deloitteconsent2023.htm	Edgar Link	pending
ex311-2023q410k.htm	Edgar Link	pending
ex312-2023q410k.htm	Edgar Link	pending
ex321-2023q410k.htm	Edgar Link	pending
ex322-2023q410k.htm	Edgar Link	pending
exhibit971-amendedclawba.htm	Edgar Link	pending
exhibit971-amendedclawba001.jpg	Edgar Link	pending
exhibit971-amendedclawba002.jpg	Edgar Link	pending
exhibit971-amendedclawba003.jpg	Edgar Link	pending
exhibit971-amendedclawba004.jpg	Edgar Link	pending
exhibit971-amendedclawba005.jpg	Edgar Link	pending
exhibit971-amendedclawba006.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
skin-20231231.htm	Edgar Link	pending
skin-20231231.xsd	Edgar Link	pending
skin-20231231_g1.jpg	Edgar Link	pending
skin-20231231_g2.jpg	Edgar Link	pending
skin-20231231_g3.jpg	Edgar Link	pending
skin-20231231_g4.jpg	Edgar Link	pending
skin-20231231_pre.xml	Edgar Link	unprocessable
skin-20231231_htm.xml	Edgar Link	completed
skin-20231231_cal.xml	Edgar Link	unprocessable
skin-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
skin-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SKIN
Beauty Health Co Stock $skin

2024 Q1 Form 10-K Financial Statement

#000162828024010638 Filed on March 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKIN Beauty Health Co Stock $skin

2024 Q1 Form 10-K Financial Statement

#000162828024010638 Filed on March 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKIN
Beauty Health Co Stock $skin